logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

On January 9th, HSBC Holdings (00005) spent approximately HK$35.61 million to repurchase 468,800 shares in Hong Kong.

date
17:26 10/01/2025
avatar
GMT Eight
HSBC Holdings (00005) announced that it will repurchase approximately 10,780,500 in the UK on January 9, 2025.
HSBC Holdings (00005) announced that on January 9, 2025, it will spend approximately 10.78 million to repurchase around 135.25 million shares in the UK, and approximately HK$35.6123 million to repurchase about 46.88 million shares in Hong Kong.
Related Articles
HK Stock
S HARBOURHOLD (01663) received the main shareholder Chen Xiangling increasing holdings by 9.2 million shares.
HK Stock
Yum China (09987) spent 7.7315 million Hong Kong dollars on January 19 to repurchase 21,000 shares.
China Stock
Shanghai Fosun Pharmaceutical (600196.SH): The Phase I/II clinical trial of HLX701 in combination with cetuximab and chemotherapy for the treatment of advanced colorectal cancer has been approved.
S HARBOURHOLD (01663) received the main shareholder Chen Xiangling increasing holdings by 9.2 million shares.
HK Stock
Yum China (09987) spent 7.7315 million Hong Kong dollars on January 19 to repurchase 21,000 shares.
HK Stock
Shanghai Fosun Pharmaceutical (600196.SH): The Phase I/II clinical trial of HLX701 in combination with cetuximab and chemotherapy for the treatment of advanced colorectal cancer has been approved.
China Stock
RECOMMEND
AI Applications Are Booming, And The Most Worth Watching May Be Hong Kong Internet
AI Applications Are Booming, And The Most Worth Watching May Be Hong Kong Internet
icon
19/01/2026
How Can China’s Retail Industry Break Free From Destructive Involutional Competition?
How Can China’s Retail Industry Break Free From Destructive Involutional Competition?
icon
19/01/2026
Equity Financing Surged 251% In 2025; Hong Kong IPO Momentum Extends Into 2026
Equity Financing Surged 251% In 2025; Hong Kong IPO Momentum Extends Into 2026
icon
19/01/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.